These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35770094)

  • 1. Functional Characterization of Two Variants at the Intron 6-Exon 7 Boundary of the KCNQ2 Potassium Channel Gene Causing Distinct Epileptic Phenotypes.
    Mosca I; Rivolta I; Labalme A; Ambrosino P; Castellotti B; Gellera C; Granata T; Freri E; Binda A; Lesca G; DiFrancesco JC; Soldovieri MV; Taglialatela M
    Front Pharmacol; 2022; 13():872645. PubMed ID: 35770094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kv7.3 Compound Heterozygous Variants in Early Onset Encephalopathy Reveal Additive Contribution of C-Terminal Residues to PIP
    Ambrosino P; Freri E; Castellotti B; Soldovieri MV; Mosca I; Manocchio L; Gellera C; Canafoglia L; Franceschetti S; Salis B; Iraci N; Miceli F; Ragona F; Granata T; DiFrancesco JC; Taglialatela M
    Mol Neurobiol; 2018 Aug; 55(8):7009-7024. PubMed ID: 29383681
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early-onset epileptic encephalopathy caused by a reduced sensitivity of Kv7.2 potassium channels to phosphatidylinositol 4,5-bisphosphate.
    Soldovieri MV; Ambrosino P; Mosca I; De Maria M; Moretto E; Miceli F; Alaimo A; Iraci N; Manocchio L; Medoro A; Passafaro M; Taglialatela M
    Sci Rep; 2016 Dec; 6():38167. PubMed ID: 27905566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two
    Tran B; Ji ZG; Xu M; Tsuchida TN; Cooper EC
    Front Physiol; 2020; 11():1144. PubMed ID: 33041849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Novel Kv7.3 Variant in the Voltage-Sensing S
    Miceli F; Carotenuto L; Barrese V; Soldovieri MV; Heinzen EL; Mandel AM; Lippa N; Bier L; Goldstein DB; Cooper EC; Cilio MR; Taglialatela M; Sands TT
    Front Physiol; 2020; 11():1040. PubMed ID: 33013448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced axonal surface expression and phosphoinositide sensitivity in K
    Kim EC; Zhang J; Pang W; Wang S; Lee KY; Cavaretta JP; Walters J; Procko E; Tsai NP; Chung HJ
    Neurobiol Dis; 2018 Oct; 118():76-93. PubMed ID: 30008368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical analysis and functional characterization of KCNQ2-related developmental and epileptic encephalopathy.
    Ye J; Tang S; Miao P; Gong Z; Shu Q; Feng J; Li Y
    Front Mol Neurosci; 2023; 16():1205265. PubMed ID: 37497102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic and functional assessment of two novel KCNQ2 gain-of-function variants Y141N and G239S and effects of amitriptyline treatment.
    Bayat A; Iavarone S; Miceli F; Jakobsen AV; Johannesen KM; Nikanorova M; Ploski R; Szymanska K; Flamini R; Cooper EC; Weckhuysen S; Taglialatela M; Møller RS
    Neurotherapeutics; 2024 Jan; 21(1):e00296. PubMed ID: 38241158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epileptic Encephalopathy In A Patient With A Novel Variant In The Kv7.2 S2 Transmembrane Segment: Clinical, Genetic, and Functional Features.
    Soldovieri MV; Ambrosino P; Mosca I; Miceli F; Franco C; Canzoniero LMT; Kline-Fath B; Cooper EC; Venkatesan C; Taglialatela M
    Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31295832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homomeric Kv7.2 current suppression is a common feature in KCNQ2 epileptic encephalopathy.
    Gomis-Pérez C; Urrutia J; Marcé-Grau A; Malo C; López-Laso E; Felipe-Rucián A; Raspall-Chaure M; Macaya A; Villarroel A
    Epilepsia; 2019 Jan; 60(1):139-148. PubMed ID: 30478917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A recurrent KCNQ2 pore mutation causing early onset epileptic encephalopathy has a moderate effect on M current but alters subcellular localization of Kv7 channels.
    Abidi A; Devaux JJ; Molinari F; Alcaraz G; Michon FX; Sutera-Sardo J; Becq H; Lacoste C; Altuzarra C; Afenjar A; Mignot C; Doummar D; Isidor B; Guyen SN; Colin E; De La Vaissière S; Haye D; Trauffler A; Badens C; Prieur F; Lesca G; Villard L; Milh M; Aniksztejn L
    Neurobiol Dis; 2015 Aug; 80():80-92. PubMed ID: 26007637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gain of function due to increased opening probability by two
    Nappi M; Barrese V; Carotenuto L; Lesca G; Labalme A; Ville D; Smol T; Rama M; Dieux-Coeslier A; Rivier-Ringenbach C; Soldovieri MV; Ambrosino P; Mosca I; Pusch M; Miceli F; Taglialatela M
    Proc Natl Acad Sci U S A; 2022 Apr; 119(15):e2116887119. PubMed ID: 35377796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gabapentin treatment in a patient with KCNQ2 developmental epileptic encephalopathy.
    Soldovieri MV; Freri E; Ambrosino P; Rivolta I; Mosca I; Binda A; Murano C; Ragona F; Canafoglia L; Vannicola C; Solazzi R; Granata T; Castellotti B; Messina G; Gellera C; Labalme A; Lesca G; DiFrancesco JC; Taglialatela M
    Pharmacol Res; 2020 Oct; 160():105200. PubMed ID: 32942014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epilepsy-causing mutations in Kv7.2 C-terminus affect binding and functional modulation by calmodulin.
    Ambrosino P; Alaimo A; Bartollino S; Manocchio L; De Maria M; Mosca I; Gomis-Perez C; Alberdi A; Scambia G; Lesca G; Villarroel A; Taglialatela M; Soldovieri MV
    Biochim Biophys Acta; 2015 Sep; 1852(9):1856-66. PubMed ID: 26073431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of KCNQ2 variants causing either benign neonatal epilepsy or developmental and epileptic encephalopathy.
    Goto A; Ishii A; Shibata M; Ihara Y; Cooper EC; Hirose S
    Epilepsia; 2019 Sep; 60(9):1870-1880. PubMed ID: 31418850
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-limited alterations in cortical activity of a knock-in mouse model of KCNQ2-related developmental and epileptic encephalopathy.
    Biba-Maazou N; Becq H; Pallesi-Pocachard E; Sarno S; Granjeaud S; Montheil A; Kurz M; Villard L; Milh M; Santini PL; Aniksztejn L
    J Physiol; 2022 May; 600(10):2429-2460. PubMed ID: 35389519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KCNQ2 R144 variants cause neurodevelopmental disability with language impairment and autistic features without neonatal seizures through a gain-of-function mechanism.
    Miceli F; Millevert C; Soldovieri MV; Mosca I; Ambrosino P; Carotenuto L; Schrader D; Lee HK; Riviello J; Hong W; Risen S; Emrick L; Amin H; Ville D; Edery P; de Bellescize J; Michaud V; Van-Gils J; Goizet C; Willemsen MH; Kleefstra T; Møller RS; Bayat A; Devinsky O; Sands T; Korenke GC; Kluger G; Mefford HC; Brilstra E; Lesca G; Milh M; Cooper EC; Taglialatela M; Weckhuysen S
    EBioMedicine; 2022 Jul; 81():104130. PubMed ID: 35780567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nine patients with KCNQ2-related neonatal seizures and functional studies of two missense variants.
    Chokvithaya S; Caengprasath N; Buasong A; Jantasuwan S; Santawong K; Leela-Adisorn N; Tongkobpetch S; Ittiwut C; Saengow VE; Kamolvisit W; Boonsimma P; Bongsebandhu-Phubhakdi S; Shotelersuk V
    Sci Rep; 2023 Feb; 13(1):3328. PubMed ID: 36849527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional characterization and in vitro pharmacological rescue of KCNQ2 pore mutations associated with epileptic encephalopathy.
    Yang GM; Tian FY; Shen YW; Yang CY; Yuan H; Li P; Gao ZB
    Acta Pharmacol Sin; 2023 Aug; 44(8):1589-1599. PubMed ID: 36932231
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.